Merck's Frazier to remain CEO of the US drugmaker beyond 2019

Merck's Frazier to remain CEO of the US drugmaker beyond 2019

Drugmaker Merck and Co Inc said on Wednesday that its board voted to rescind a policy requiring its head to retire at 65, a move that will permit current Chief Executive Officer Kenneth Frazier to remain in the role beyond next year.

FILE PHOTO -  Chairman and CEO of Merck & Co., Kenneth Frazier, takes part in a panel discussio
FILE PHOTO - Chairman and CEO of Merck & Co., Kenneth Frazier, takes part in a panel discussion during the Clinton Global Initiative's annual meeting in New York, September 27, 2015. REUTERS/Brendan McDermid

REUTERS: Merck & Co Inc Chief Executive Officer Kenneth Frazier will remain in the role beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEOs to retire at the age of 65.

Frazier, who will turn 65 in December 2019, took the helm of the U.S. pharmaceutical company in 2011. On his watch, the company's stock price has doubled and its cancer immunotherapy Keytruda has raked in blockbuster sales, becoming one of the leading products in a new generation of oncology treatments.

"CEO succession has been our top priority, and removing the mandatory retirement policy enables the Board to make the best decision concerning the timing of that transition," Merck's lead director Leslie Brun said in a statement.

Frazier made headlines last year when he became the first business leader to leave U.S. President Donald Trump's now disbanded manufacturing council following Trump's comments on a white nationalist rally held in Charlottesville, Virginia.

The grandson of a sharecropper, and son of a janitor, Frazier's appointment to CEO in 2011 made him the only black person leading one of the major U.S. or European drugmakers.

Frazier made his name at Merck as the company's general counsel, steering the company through daunting litigation over Vioxx, its widely used painkiller that was withdrawn from the market in 2004 after being linked to heart attacks.

Merck eventually paid nearly US$5 billion to settle some 27,000 lawsuits brought by those who claimed to have been harmed by the popular arthritis treatment.

As chief executive, Frazier has focused the company around the development Keytruda, which has racked up approvals to treat numerous types of cancer, including lung cancer. Analysts expect annual Keytruda sales to reach nearly US$11 billion by 2020 and keep climbing from there, according to Thomson Reuters data.

Under Frazier, Merck also announced price cuts for some of its medicines in July, including a 60 percent reduction on a hepatitis C treatment, after Trump criticized drugmakers for failing to help reduce healthcare costs for consumers.

Merck's shares were up 21 cents at US$70.86 on Wednesday.

(Reporting by Tamara Mathias in Bengaluru and Michael Erman in New York; Editing by Shailesh Kuber, Sai Sachin Ravikumar and Bill Berkrot)

Source: Reuters